EBQ:Cephalosporin Cross-reactivity: Difference between revisions
Ostermayer (talk | contribs) No edit summary |
(Added all standard JC sections) |
||
| (17 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
[[penicillins | ==Background== | ||
Previously, [[penicillins]] (PCN) and [[cephalosporins]] were produced with the same fungi during synthesis. This increased the rate of cross contamination especially prior to 1980. Although the allergy was though to be due to the similarities in the beta-lactam ring it is more probably caused due to manufacturing contamination although there is cross reactivity risk based on side chain similarity. 1st and 2nd generation [[penicillins]] share the same R-1 side chain.<ref>UIC Pharmacology on Penicillin Cross Reactivity https://www.uic.edu/pharmacy/services/di/crossens.htm</ref> However, a current review of the literature demonstrates that the 10% or greater allergy may be exaggerated.<ref name="campagna">Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: A literature review. J Emerg Med. 2012;42(5):612-20</ref> | |||
* 1st generation | ==Cross-Reaction Risk== | ||
* | * Overall cross-reactivity rate between [[cephalosporins]] and [[penicillins]] in patients reporting a penicillin allergy = 1%. <ref name="campagna"></ref> | ||
* Overall cross-reactivity rate in patients with a confirmed penicillin allergy = 2.5%. <ref name="campagna"></ref> | |||
* Cross-reactivity between [[penicillins]] and 1st and 2nd generation [[cephalosporins]] is possible.<ref name="campagna"></ref> | |||
* Cross-reactivity between [[penicillins]] and ALL 3rd and 4th generation [[cephalosporins]] is negligible.<ref name="campagna"></ref> | |||
== | ==Antibiotic Categories== | ||
* | {{Beta-lactams}} | ||
* | |||
* Cross-reactivity between | ==External Links== | ||
* Cross-reactivity | *[https://umem.org/educational_pearls/2540/ UMEM - Penicillin Cephalosporin Cross-Reactivity Made Easy] | ||
* | |||
==Clinical Question== | |||
What is the true cross-reactivity rate between penicillins and cephalosporins, and can cephalosporins be safely administered to patients with penicillin allergy? | |||
==Conclusion== | |||
*The historical cross-reactivity rate of 10% between penicillins and cephalosporins is a significant overestimate | |||
*True cross-reactivity is approximately 1-2% and is mediated by similar R1 side chains, not the beta-lactam ring | |||
*Most patients with reported penicillin allergy can safely receive cephalosporins, particularly those with dissimilar side chains | |||
==Study Design== | |||
*Systematic review and analysis of published literature on penicillin-cephalosporin cross-reactivity | |||
*Reviewed multiple studies spanning several decades of allergy testing and clinical outcomes data | |||
==Population== | |||
*Patients with reported penicillin allergy requiring antibiotic therapy | |||
*Studies included both skin-test confirmed and self-reported penicillin allergy | |||
==Interventions== | |||
*Administration of cephalosporins to patients with penicillin allergy | |||
*Penicillin skin testing in some studies to confirm allergy before cephalosporin challenge | |||
==Outcomes== | |||
*Cross-reactivity between penicillins and first-generation cephalosporins: approximately 1-2% | |||
*Cross-reactivity with second and third-generation cephalosporins: <1% | |||
*Cross-reactivity is mediated by shared R1 side chains (e.g., amoxicillin-cephalexin share side chain) | |||
*The 10% cross-reactivity rate originated from early studies using contaminated cephalosporin preparations | |||
==Criticisms== | |||
*Many studies relied on self-reported penicillin allergy without skin testing confirmation | |||
*True IgE-mediated penicillin allergy is present in <10% of patients reporting penicillin allergy | |||
*Retrospective data cannot fully capture all allergic reactions, particularly delayed reactions | |||
*Clinical decision-making must still account for the rare but potentially fatal anaphylaxis risk | |||
*Skin testing availability varies widely and is not routinely performed in the ED | |||
==Funding== | |||
*Variable across reviewed studies | |||
==See Also== | ==See Also== | ||
*[[Cephalosporins]] | *[[Cephalosporins]] | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:EBQ]] | [[Category:EBQ]] | ||
[[Category: | [[Category:Pharmacology]] | ||
Latest revision as of 22:50, 21 March 2026
Background
Previously, penicillins (PCN) and cephalosporins were produced with the same fungi during synthesis. This increased the rate of cross contamination especially prior to 1980. Although the allergy was though to be due to the similarities in the beta-lactam ring it is more probably caused due to manufacturing contamination although there is cross reactivity risk based on side chain similarity. 1st and 2nd generation penicillins share the same R-1 side chain.[1] However, a current review of the literature demonstrates that the 10% or greater allergy may be exaggerated.[2]
Cross-Reaction Risk
- Overall cross-reactivity rate between cephalosporins and penicillins in patients reporting a penicillin allergy = 1%. [2]
- Overall cross-reactivity rate in patients with a confirmed penicillin allergy = 2.5%. [2]
- Cross-reactivity between penicillins and 1st and 2nd generation cephalosporins is possible.[2]
- Cross-reactivity between penicillins and ALL 3rd and 4th generation cephalosporins is negligible.[2]
Antibiotic Categories
| |||||||||||||||||||||||||||||||||||||||||
External Links
Clinical Question
What is the true cross-reactivity rate between penicillins and cephalosporins, and can cephalosporins be safely administered to patients with penicillin allergy?
Conclusion
- The historical cross-reactivity rate of 10% between penicillins and cephalosporins is a significant overestimate
- True cross-reactivity is approximately 1-2% and is mediated by similar R1 side chains, not the beta-lactam ring
- Most patients with reported penicillin allergy can safely receive cephalosporins, particularly those with dissimilar side chains
Study Design
- Systematic review and analysis of published literature on penicillin-cephalosporin cross-reactivity
- Reviewed multiple studies spanning several decades of allergy testing and clinical outcomes data
Population
- Patients with reported penicillin allergy requiring antibiotic therapy
- Studies included both skin-test confirmed and self-reported penicillin allergy
Interventions
- Administration of cephalosporins to patients with penicillin allergy
- Penicillin skin testing in some studies to confirm allergy before cephalosporin challenge
Outcomes
- Cross-reactivity between penicillins and first-generation cephalosporins: approximately 1-2%
- Cross-reactivity with second and third-generation cephalosporins: <1%
- Cross-reactivity is mediated by shared R1 side chains (e.g., amoxicillin-cephalexin share side chain)
- The 10% cross-reactivity rate originated from early studies using contaminated cephalosporin preparations
Criticisms
- Many studies relied on self-reported penicillin allergy without skin testing confirmation
- True IgE-mediated penicillin allergy is present in <10% of patients reporting penicillin allergy
- Retrospective data cannot fully capture all allergic reactions, particularly delayed reactions
- Clinical decision-making must still account for the rare but potentially fatal anaphylaxis risk
- Skin testing availability varies widely and is not routinely performed in the ED
Funding
- Variable across reviewed studies